| Assessment Status | Rapid Review Complete |
| HTA ID | 26057 |
| Drug | Formoterol fumarate dihydrate/glycopyrronium bromide/budesonide |
| Brand | Trixeo Aerosphere® |
| Indication | Formoterol fumarate dihydrate/glycopyrronium bromide/budesonide (Trixeo Aerosphere®) as a maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and a long-acting beta2-agonist. |
| Assessment Process | |
| Rapid review commissioned | 08/10/2026 |
| Rapid review completed | 03/11/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that formoterol fumarate dihydrate/glycopyrronium bromide/budesonide (Trixeo Aerosphere®) not be considered for reimbursement, for this indication, at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here